Sun Pharmaceutical Industries · NSE: SUNPHARMA · BSE: 524715

Q3 FY22 results · Oct–Dec 2021

Sun Pharmaceutical Industries reported revenue from operations of ₹9,863.06 crore (up 11.6% from Q3 FY21) and net profit of ₹2,126.28 crore (up 11.1% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY22	Q3 FY21	YoY	Q2 FY22	QoQ
Revenue from operations	9,863.06	8,836.78	+11.6%	9,625.93	+2.5%
Other income	432.51	314.95	+37.3%	222.89	+94.0%
Total income	10,295.57	9,151.73	+12.5%	9,848.82	+4.5%
Profit before share of associates & JVs and tax	2,466.19	2,163.05	+14.0%	2,286.51	+7.9%
Share of profit/(loss) of associates & JVs	(4.52)	(4.70)		(2.39)
Net profit for the period	2,126.28	1,913.41	+11.1%	2,086.34	+1.9%
Attributable to shareholders of the company	2,058.80	1,852.48	+11.1%	2,047.01	+0.6%
EPS, basic (₹)	8.60	7.72	+11.4%	8.50	+1.2%
Net margin (%)	21.6	21.7		21.7

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q3 FY22	Q3 FY21	YoY	Q2 FY22	QoQ
Revenue from operations	3,770.66	3,388.02	+11.3%	4,143.15	−9.0%
Other income	305.23	20.98	15x	284.27	+7.4%
Total income	4,075.89	3,409.00	+19.6%	4,427.42	−7.9%
Profit before tax	520.91	548.40	−5.0%	710.92	−26.7%
Net profit for the period	515.43	555.55	−7.2%	809.07	−36.3%
EPS, basic (₹)	2.10	2.32	−9.5%	3.40	−38.2%
Net margin (%)	13.7	16.4		19.5

Consolidated

Filed with BSE: 31 Jan 2022, 18:44 IST
Board meeting: 31 Jan 2022
Period: 01 Oct 2021 to 31 Dec 2021
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 31 Jan 2022, 18:44 IST
Board meeting: 31 Jan 2022
Period: 01 Oct 2021 to 31 Dec 2021
Review status: Unaudited
Source: XBRL filing on BSE